Cargando…
Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment
Diabetes mellitus is a chronic multisystem disease with a high global prevalence. The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to lower glucose levels and reduce weight. However, the mechanisms underlying the benefits of liraglutide treatment in patients with type 2 diab...
Autores principales: | Rafiullah, Mohamed, Benabdelkamel, Hicham, Masood, Afshan, Ekhzaimy, Aishah A., Musambil, Mohthash, Joy, Salini Scaria, Alfadda, Assim A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956006/ https://www.ncbi.nlm.nih.gov/pubmed/36826037 http://dx.doi.org/10.3390/cimb45020092 |
Ejemplares similares
-
Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment
por: Ekhzaimy, Aishah A, et al.
Publicado: (2022) -
Proteomic profiling of thyroid tissue in patients with obesity and benign diffuse goiter
por: Benabdelkamel, Hicham, et al.
Publicado: (2022) -
Exploring Cardio-Metabolic Effects of Liraglutide in Patients With Type 2 Diabetes Through a Proteomic Approach
por: Ekhzaimy, Aishah Ali, et al.
Publicado: (2021) -
Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment
por: Masood, Afshan, et al.
Publicado: (2020) -
Proteomics Profiling of the Urine of Patients with Hyperthyroidism after Anti-Thyroid Treatment
por: Benabdelkamel, Hicham, et al.
Publicado: (2021)